2025 Financial Guidance
To advance our strategy and expand our leadership in Fabry and Pompe disease, our financial guidance for 2025 is as follows:
| Total Revenue Growth1 | 17% to 24% |
| Galafold Revenue Growth1 | 10% to 15% |
| Pombiliti + Opfolda Growth1 | 65% to 85% |
| Gross Margin | Mid 80% |
| Non-GAAP Operating Expenses4 | $350M to $370M |
| GAAP Net Income | Positive during H2 2025 |
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。